Cure My Disease

Don't miss your cure!

 Log in / Sign up

A Finger-Prick at the pharmacy could uncover silent diabetes

NCT ID NCT07795918

Diagnosis Sponsor: Universiti Sains Malaysia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

This study tests whether community pharmacies can help find undiagnosed type 2 diabetes and prediabetes in adults living in Irbid, Jordan. Participants without a diabetes diagnosis will fill out a risk questionnaire and, if their score is high, receive a quick finger-prick HbA1c test at the pharmacy. Those with abnormal results will be referred to a doctor for confirmation and follow-up. The goal is to see how many people fall into each risk category and how many high-risk individuals actually have diabetes or prediabetes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Finnish Diabetes Risk Score questionnaire and point-of-care HbA1c testing
What this could lead to
If it works, this could point toward a simple, pharmacy-based way to catch type 2 diabetes and prediabetes earlier, especially in places where healthcare access is limited.
What could go wrong
This is an observational study, so it cannot prove that pharmacy testing improves health outcomes. The results may not apply beyond the specific region, and the accuracy of HbA1c tests can be affected by certain conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 480 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of adults visiting participating community pharmacies in Irbid Governorate, Jordan, who have no previous diagnosis of diabetes. Participants will be recruited through convenience sampling during routine pharmacy visits. Those classified as having a high or very high diabetes risk will receive community pharmacy-based point-of-care HbA1c testing. Participants with GP-confirmed type 2 diabetes will enter the six-month follow-up cohort.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or older * Lives in Irbid Governorate, Jordan * Visits a participating community pharmacy * Has not previously been diagnosed with diabetes * Can understand and complete the study procedures * Provides written informed consent Exclusion Criteria: * Previous diagnosis of diabetes * Pregnancy * Known anemia * Known hemoglobin disorder * Blood transfusion within the previous three months * A condition that may make the HbA1c result inaccurate * A cognitive or communication difficulty that prevents informed consent or

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus, type 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus, type 2 Prediabetes / type 2 diabetes Prediabetic state T2DM

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Khaled Pharmacy

    Irbid, Irbid Governorate, Jordan

More trials for these conditions

Other studies related to the condition(s) this trial covers.